Inhibition of the BGR-ABL tyrosine kinase for the treatment of chronic myeloid leukemia

被引：0
|
作者：
Coulombel, L [1 ]
机构：
[1] INSERM U474, F-75014 Paris, France
来源：
M S-MEDECINE SCIENCES | 2001年 / 17卷 / 8-9期
关键词：
D O I：
10.4267/10608/2038
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：952 / 953
页数：2
相关论文
共 50 条
  • [41] BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survival
    Barbosa Pagnano, Katia Borgia
    Bendit, Israel
    Boquimpani, Carla
    De Souza, Carmino Antonio
    Miranda, Eliana C. M.
    Zalcberg, Ilana
    Larripa, Irene
    Nardinelli, Luciana
    Silveira, Rosana Antunes
    Fogliatto, Laura
    Spector, Nelson
    Funke, Vaneuza
    Pasquini, Ricardo
    Hungria, Vania
    Chiattone, Carlos Sergio
    Clementino, Nelma
    Conchon, Monika
    Beatriz Moiraghi, Elena
    Lopez, Jose Luis
    Pavlovsky, Carolina
    Pavlovsky, Miguel A.
    Cervera, Eduardo E.
    Antonio Meillon, Luis
    Simoes, Belinda
    Hamerschlak, Nelson
    Magarinos Bozzano, Alicia Helena
    Mayta, Ernesto
    Cortes, Jorge
    Bengio, Raquel M.
    CANCER INVESTIGATION, 2015, 33 (09) : 451 - 458
  • [42] Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
    Druker, BJ
    Talpaz, M
    Resta, DJ
    Peng, B
    Buchdunger, E
    Ford, JM
    Lydon, NB
    Kantarjian, H
    Capdeville, R
    Ohno-Jones, S
    Sawyers, CL
    NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14): : 1031 - 1037
  • [43] Chronic myeloid leukemia and resistance to tyrosine kinase inhibitors: ABL mutations, much ado about nothing?
    Gomez Casares, Maria Teresa
    Leon, Leticia G.
    MEDICINA CLINICA, 2013, 141 (03): : 111 - 113
  • [44] ANALYSIS OF THE REACTIVATION OF HEPATITIS B VIRUS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN TREATMENT WITH INHIBITORS OF THE TYROSINE KINASE BCR-ABL
    Sanz Ruperez, A.
    Ruiz Gomez, F.
    Garcia Gutierrez, V
    Herrera Puente, P.
    Calbacho Robles, M.
    Velazquez Kennedy, K.
    Geijo Roman, Martinez C.
    Lopez Jimenez, J.
    HAEMATOLOGICA, 2017, 102 : 279 - 279
  • [45] Discontinuation of BCR-ABL tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a retrospective study
    Iino, Masaki
    ANNALS OF ONCOLOGY, 2017, 28
  • [46] The Effect of BCR-ABL Specific Tyrosine Kinase Inhibitors on the Thioredoxin System in Chronic Myeloid Leukemia
    Clapper, Erin
    Di Trapani, Giovanna
    Tonissen, Kathryn F.
    HEMATO, 2021, 2 (02): : 237 - 254
  • [47] THE RATE OF BCR-ABL DECLINE AS AN OPTIMIZED PREDICTOR OF OUTCOME FOR PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE ON TREATMENT WITH TYROSINE KINASE INHIBITORS
    Fominykh, M.
    Shuvaev, V.
    Martynkevich, I.
    Tsaur, G.
    Bederak, N.
    Chelysheva, E.
    Shukhov, O.
    Abdullaev, A.
    Udaleva, V.
    Golovchenko, R.
    Zotova, I.
    Shikhbabaeva, D.
    Polushkina, L.
    Petrova, E.
    Ivanova, M.
    Martynenko, L.
    Kleina, E.
    Cybakova, N.
    Turkina, A.
    Abdulkadyrov, K.
    HAEMATOLOGICA, 2015, 100 : 444 - 444
  • [48] Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors
    Gugliotta, Gabriele
    Castagnetti, Fausto
    Fogli, Miriam
    Cavo, Michele
    Baccarani, Michele
    Rosti, Gianantonio
    EXPERT REVIEW OF HEMATOLOGY, 2013, 6 (05) : 563 - 574
  • [49] Tyrosine kinase inhibitor treatment discontinuation in chronic myeloid leukemia: patient views
    Tromp, Vashti N. M. F.
    Timmers, Lonneke
    Koningen, Leanne
    Janssen, Jeroen J. W. M.
    Westerweel, Peter E.
    Geelen, Inge G. P.
    de Jong, Jan
    Beckeringh, Jan J.
    Boons, Christel C. L. M.
    Hugtenburg, Jacqueline G.
    LEUKEMIA & LYMPHOMA, 2021, 62 (03) : 649 - 658
  • [50] Treatment of Chronic Myeloid Leukemia Elderly Patients in the Tyrosine Kinase Inhibitor Era
    Russo, Domenico
    Malagola, Michele
    Skert, Cristina
    Fili, Carla
    Bergonzi, Cesare
    Cancelli, Valeria
    Cattina, Federica
    CURRENT CANCER DRUG TARGETS, 2013, 13 (07) : 755 - 767
12345